INMB
INmune Bio, Inc.
Biotechnology
Market Cap$38M
5Y Perf.-74.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
INMB vs SAVA vs ACAD vs AVXL
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$94M
5Y Perf.+645.8%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.6%
AVXL
Anavex Life Sciences Corp.
Biotechnology
Market Cap$289M
5Y Perf.-24.1%
INMB vs SAVA vs ACAD vs AVXL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | INMB | SAVA | ACAD | AVXL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $38M | $94M | $3.86B | $289M |
| Revenue (TTM) | $0.00 | $0.00 | $1.10B | $0.00 |
| Net Income (TTM) | $-42M | $-106M | $376M | $-40M |
| Gross Margin | 100.0% | — | 91.5% | — |
| Operating Margin | -617.4% | — | 7.4% | — |
| Forward P/E | — | — | 50.9x | — |
| Total Debt | $1M | $0.00 | $52M | $0.00 |
| Cash & Equiv. | $25M | $129M | $178M | $103M |
INMB vs SAVA vs ACAD vs AVXL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INMB
SAVA
ACAD
AVXL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| INmune Bio, Inc. (INMB) | 100 | 25.1 | -74.9% |
| Cassava Sciences, I… (SAVA) | 100 | 745.8 | +645.8% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.4 | -54.6% |
| Anavex Life Science… (AVXL) | 100 | 75.9 | -24.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INMB vs SAVA vs ACAD vs AVXL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. INmune Bio, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
INMB
INmune Bio, Inc.
The Growth Play
INMB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 257.1%, EPS growth 11.8%, 3Y rev CAGR -48.9%
- 257.1% revenue growth vs SAVA's -5.4%
Best for: growth exposure
SAVA
Cassava Sciences, Inc.
The Long-Run Compounder
SAVA is the clearest fit if your priority is long-term compounding.
- -19.5% 10Y total return vs ACAD's -22.9%
Best for: long-term compounding
ACAD
ACADIA Pharmaceuticals Inc.
The Income Pick
ACAD carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.26
- Lower volatility, beta 1.26, Low D/E 4.3%, current ratio 3.83x
- Beta 1.26, current ratio 3.83x
- 34.3% margin vs INMB's -918.7%
Best for: income & stability and sleep-well-at-night
AVXL
Anavex Life Sciences Corp.
The Secondary Option
AVXL lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | INMB | 257.1% revenue growth vs SAVA's -5.4% |
| Quality / Margins | ACAD | 34.3% margin vs INMB's -918.7% |
| Stability / Safety | ACAD | Beta 1.26 vs INMB's 2.45, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | ACAD | +52.4% vs INMB's -80.0% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs INMB's -128.8%, ROIC 10.0% vs -407.4% |
INMB vs SAVA vs ACAD vs AVXL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2018
Segment breakdown not available.
INMB vs SAVA vs ACAD vs AVXL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGAVXL
Who Leads Where
ACAD leads in 4 of 6 categories
INMB leads 0 • SAVA leads 0 • AVXL leads 0 • 1 tied
Explore the data ↓AVXLAnavex Life Sciences …
0leads
SAVACassava Sciences, Inc.
0leads
INMBINmune Bio, Inc.
0leads
ACADACADIA Pharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs INMBvs SAVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ACAD4/6
Risk & VolatilityBeta, volatility, and downside exposure
ACAD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and AVXL operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to INMB's -918.7%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | INMBINmune Bio, Inc. | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $1.1B | $0 |
| EBITDAEarnings before interest/tax | -$27M | -$110M | $96M | -$30M |
| Net IncomeAfter-tax profit | -$42M | -$106M | $376M | -$40M |
| Free Cash FlowCash after capex | -$21M | -$84M | $212M | -$34M |
| Gross MarginGross profit ÷ Revenue | +100.0% | — | +91.5% | — |
| Operating MarginEBIT ÷ Revenue | -617.4% | — | +7.4% | — |
| Net MarginNet income ÷ Revenue | -918.7% | — | +34.3% | — |
| FCF MarginFCF ÷ Revenue | -472.5% | — | +19.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — | +9.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +53.5% | +62.1% | -81.8% | +54.4% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — SAVA and ACAD and AVXL each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | INMBINmune Bio, Inc. | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| Market CapShares × price | $38M | $94M | $3.9B | $289M |
| Enterprise ValueMkt cap + debt − cash | $14M | -$34M | $3.7B | $187M |
| Trailing P/EPrice ÷ TTM EPS | -0.77x | -3.76x | 9.85x | -5.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 50.91x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 26.91x | — |
| Price / SalesMarket cap ÷ Revenue | 760.34x | — | 3.61x | — |
| Price / BookPrice ÷ Book value/share | 1.62x | 0.63x | 3.15x | 2.81x |
| Price / FCFMarket cap ÷ FCF | — | — | 36.74x | — |
Evenly matched — SAVA and ACAD and AVXL each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-171 for INMB. ACAD carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to INMB's 0.04x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs AVXL's 2/9, reflecting solid financial health.
| Metric | INMBINmune Bio, Inc. | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -170.9% | -95.8% | +35.6% | -31.5% |
| ROA (TTM)Return on assets | -128.8% | -75.3% | +26.2% | -30.0% |
| ROICReturn on invested capital | -4.1% | -6.3% | +10.0% | — |
| ROCEReturn on capital employed | -109.7% | -99.9% | +10.1% | -47.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 6 | 2 |
| Debt / EquityFinancial leverage | 0.04x | — | 0.04x | — |
| Net DebtTotal debt minus cash | -$24M | -$129M | -$126M | -$103M |
| Cash & Equiv.Liquid assets | $25M | $129M | $178M | $103M |
| Total DebtShort + long-term debt | $1M | $0 | $52M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — | — | — |
ACAD leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ACAD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACAD five years ago would be worth $10,710 today (with dividends reinvested), compared to $1,338 for INMB. Over the past 12 months, ACAD leads with a +52.4% total return vs INMB's -80.0%. The 3-year compound annual growth rate (CAGR) favors ACAD at 1.5% vs INMB's -44.5% — a key indicator of consistent wealth creation.
| Metric | INMBINmune Bio, Inc. | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.1% | -6.5% | -13.7% | -15.2% |
| 1-Year ReturnPast 12 months | -80.0% | +25.3% | +52.4% | -63.2% |
| 3-Year ReturnCumulative with dividends | -82.9% | -40.8% | +4.7% | -62.9% |
| 5-Year ReturnCumulative with dividends | -86.6% | -67.0% | +7.1% | -72.4% |
| 10-Year ReturnCumulative with dividends | -82.1% | -19.5% | -22.9% | -25.7% |
| CAGR (3Y)Annualised 3-year return | -44.5% | -16.0% | +1.5% | -28.1% |
ACAD leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ACAD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACAD is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than INMB's 2.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 81.1% from its 52-week high vs INMB's 12.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INMBINmune Bio, Inc. | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.45x | 2.02x | 1.26x | 1.51x |
| 52-Week HighHighest price in past year | $11.64 | $4.98 | $27.81 | $13.99 |
| 52-Week LowLowest price in past year | $1.09 | $1.51 | $14.45 | $2.61 |
| % of 52W HighCurrent price vs 52-week peak | +12.3% | +39.3% | +81.1% | +22.3% |
| RSI (14)Momentum oscillator 0–100 | 59.2 | 46.8 | 44.2 | 47.0 |
| Avg Volume (50D)Average daily shares traded | 384K | 712K | 1.8M | 1.4M |
ACAD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SAVA as "Buy", ACAD as "Buy", AVXL as "Buy". Consensus price targets imply 252.6% upside for AVXL (target: $11) vs 54.1% for ACAD (target: $35).
| Metric | INMBINmune Bio, Inc. | SAVACassava Sciences,… | ACADACADIA Pharmaceut… | AVXLAnavex Life Scien… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $34.78 | $11.00 |
| # AnalystsCovering analysts | — | 12 | 37 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 4 of 6 categories
Loading custom metrics...
INMB vs SAVA vs ACAD vs AVXL: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is INMB or SAVA or ACAD or AVXL a better buy right now?
For growth investors, INmune Bio, Inc.
(INMB) is the stronger pick with 257. 1% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Cassava Sciences, Inc. (SAVA) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INMB or SAVA or ACAD or AVXL?
Over the past 5 years, ACADIA Pharmaceuticals Inc.
(ACAD) delivered a total return of +7. 1%, compared to -86. 6% for INmune Bio, Inc. (INMB). Over 10 years, the gap is even starker: SAVA returned -19. 5% versus INMB's -82. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INMB or SAVA or ACAD or AVXL?
By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.
(ACAD) is the lower-risk stock at 1. 26β versus INmune Bio, Inc. 's 2. 45β — meaning INMB is approximately 95% more volatile than ACAD relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 4% for INmune Bio, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — INMB or SAVA or ACAD or AVXL?
By revenue growth (latest reported year), INmune Bio, Inc.
(INMB) is pulling ahead at 257. 1% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -3. 8% for Anavex Life Sciences Corp.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INMB or SAVA or ACAD or AVXL?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -918. 7% for INmune Bio, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -617. 4% for INMB. At the gross margin level — before operating expenses — INMB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is INMB or SAVA or ACAD or AVXL more undervalued right now?
Analyst consensus price targets imply the most upside for AVXL: 252.
6% to $11. 00.
07Which pays a better dividend — INMB or SAVA or ACAD or AVXL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is INMB or SAVA or ACAD or AVXL better for a retirement portfolio?
For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). INmune Bio, Inc. (INMB) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -22. 9%, INMB: -82. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between INMB and SAVA and ACAD and AVXL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INMB is a small-cap high-growth stock; SAVA is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; AVXL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.